Ask Us > Intralipid promotion into Ukraine
Hi Volodymyr,
No, I do not receive ANY funds from ANY pharma company. Strangely, I pay for the domain name and website and do all maintenance myself. Now, as you to your question. My main question about lipofundin has to do with sodium oleate which is listed as a component. This is a problem since administering an emulsion of fatty acid is safe, but the sodium salt could theoretically cause lung injury. The medium-long chain dilemma is less important, since we already have evidence that medialipid works. Remind the authorities that the cost of a single bottle of liposyn is cheap compared to an unnecessary death. Let me know if you'd li8ke me to write a letter.
Regards,
Guy.
No, I do not receive ANY funds from ANY pharma company. Strangely, I pay for the domain name and website and do all maintenance myself. Now, as you to your question. My main question about lipofundin has to do with sodium oleate which is listed as a component. This is a problem since administering an emulsion of fatty acid is safe, but the sodium salt could theoretically cause lung injury. The medium-long chain dilemma is less important, since we already have evidence that medialipid works. Remind the authorities that the cost of a single bottle of liposyn is cheap compared to an unnecessary death. Let me know if you'd li8ke me to write a letter.
Regards,
Guy.
August 27, 2009 |
[Guy Weinberg]
[Guy Weinberg]
Dear Professor,
Thousand thanks for your answer, your readiness to help, your invention of "lipid rescue", and your philanthropic work at this website.
In no way I suspect any conflict of interests.
BTW, it's rather strange that manufacturers of Intralipid or Lipofundin take no part in the deal.
Mazoit et al used Intralipid from Fresenius Kabi, Shah et al (J Anesth 2009; 23:439-441) used Intralipid from Baxter.
As I told, in Ukraine we have Lipofundin only.
A la guerre comme a la guerre, we buy Lipofundin for our working places.
But now we, Professor Kobeliatsky from Dnipropetrovsk Medical Academy and me, working at Kharkiv Postgraduate Medical Academy, have a commission to write a draft of guidelines for LA toxicity management.
My proposition was to recommend "lipid emulsion (Intralipid or Lipofundin)", but Professor Kobeliatsky objected: "How can we recommend Lipofundin without any evidence of its effectiveness?"
Intralipid from Fresenius Kabi is licensed in Ukraine. But nobody can buy it here. Fresenius Kabi reps in Ukraine are lazy guys and do nothing.
So, I see two problems.
First, what to write in the forementioned draft?
Second, where to get address of the pan-European product-manager of the Intralipid?
Googling has brought me advertising for share-holders only :-(
BTW, what's liposyn?
And what harm can sodium oleate do, besides sodium load?
Thousand thanks for your advice,
Volodymyr Fesenko, anesthesiologist,
Dept of Traumatology, Vertebrology, and Anesthesiology,
Kharkiv Postgraduate Medical Academy,
58 Korchagintsiv Street,
Kharkiv, 61176,
Ukraine
vfesenko@yahoo.com
Thousand thanks for your answer, your readiness to help, your invention of "lipid rescue", and your philanthropic work at this website.
In no way I suspect any conflict of interests.
BTW, it's rather strange that manufacturers of Intralipid or Lipofundin take no part in the deal.
Mazoit et al used Intralipid from Fresenius Kabi, Shah et al (J Anesth 2009; 23:439-441) used Intralipid from Baxter.
As I told, in Ukraine we have Lipofundin only.
A la guerre comme a la guerre, we buy Lipofundin for our working places.
But now we, Professor Kobeliatsky from Dnipropetrovsk Medical Academy and me, working at Kharkiv Postgraduate Medical Academy, have a commission to write a draft of guidelines for LA toxicity management.
My proposition was to recommend "lipid emulsion (Intralipid or Lipofundin)", but Professor Kobeliatsky objected: "How can we recommend Lipofundin without any evidence of its effectiveness?"
Intralipid from Fresenius Kabi is licensed in Ukraine. But nobody can buy it here. Fresenius Kabi reps in Ukraine are lazy guys and do nothing.
So, I see two problems.
First, what to write in the forementioned draft?
Second, where to get address of the pan-European product-manager of the Intralipid?
Googling has brought me advertising for share-holders only :-(
BTW, what's liposyn?
And what harm can sodium oleate do, besides sodium load?
Thousand thanks for your advice,
Volodymyr Fesenko, anesthesiologist,
Dept of Traumatology, Vertebrology, and Anesthesiology,
Kharkiv Postgraduate Medical Academy,
58 Korchagintsiv Street,
Kharkiv, 61176,
Ukraine
vfesenko@yahoo.com
August 28, 2009 |
Volodymyr Fesenko
Volodymyr Fesenko
Hi Vlod,
thanks for providing the background to your situation. aussi, la plus ca change, etc.
the formulation i would consider if intralipid is unavailable is liposyn. it is essentially the same formulation of soy oil by a different manufacturer. the concern about oleate is that a non-emulsified, free fatty acid infused into the blood stream can cause acute lung injury. i can send you the reference later. meantime, lets check to confirm if lipofundin has oleate and the concentration.
regarding the recommendations, you have two options. the AAGBI (see their website) has guidelines from a year or so ago; the ASRA working group is ready to publish their recommendations for treating LA toxicity in the next few months. i can get you and advance copy if you include the ASRA logo or cite our working group as a source.
finally, i think you shoujld be able to pressure fresenius to help you. i might also be able to help in some way. we'll see.
regards,
guy
thanks for providing the background to your situation. aussi, la plus ca change, etc.
the formulation i would consider if intralipid is unavailable is liposyn. it is essentially the same formulation of soy oil by a different manufacturer. the concern about oleate is that a non-emulsified, free fatty acid infused into the blood stream can cause acute lung injury. i can send you the reference later. meantime, lets check to confirm if lipofundin has oleate and the concentration.
regarding the recommendations, you have two options. the AAGBI (see their website) has guidelines from a year or so ago; the ASRA working group is ready to publish their recommendations for treating LA toxicity in the next few months. i can get you and advance copy if you include the ASRA logo or cite our working group as a source.
finally, i think you shoujld be able to pressure fresenius to help you. i might also be able to help in some way. we'll see.
regards,
guy
August 28, 2009 |
[Guy Weinberg]
[Guy Weinberg]
Dear Guy,
First of all, Fresenius has already brought Intralipid to Dnipropetrovsk.
So, we in Kharkiv can buy it, too.
Hurrah!
Now our guidelines draft is the only problem.
I have 2007 AAGBI guidelines and took them as an example.
They recommend "lipid emulsions" adding in comments that in all the published cases Intralipid only was used.
So, my first question is:
Maybe, it'll be good to write: "lipid emulsions (Intralipid or Liposyn)" ?
I'll be grateful for ASRA working group draft, too.
As to copy-right, my another question is:
May I quote it in future articles in Ukrainian (for anesthesthetic journal distributed in Ukraine) and in Russian (for the journal 'Emergency Medicine' distributed both in Ukraine and in Russia)?
Surely, we'll cite your working group as a source (it'll increase the trust in our information). The Globe must know its Heroes :)
Thousand thanks in advance!
First of all, Fresenius has already brought Intralipid to Dnipropetrovsk.
So, we in Kharkiv can buy it, too.
Hurrah!
Now our guidelines draft is the only problem.
I have 2007 AAGBI guidelines and took them as an example.
They recommend "lipid emulsions" adding in comments that in all the published cases Intralipid only was used.
So, my first question is:
Maybe, it'll be good to write: "lipid emulsions (Intralipid or Liposyn)" ?
I'll be grateful for ASRA working group draft, too.
As to copy-right, my another question is:
May I quote it in future articles in Ukrainian (for anesthesthetic journal distributed in Ukraine) and in Russian (for the journal 'Emergency Medicine' distributed both in Ukraine and in Russia)?
Surely, we'll cite your working group as a source (it'll increase the trust in our information). The Globe must know its Heroes :)
Thousand thanks in advance!
August 29, 2009 |
Volodymyr Fesenko
Volodymyr Fesenko
Hi V,
those are all good suggestions. good luck on your proposed guidelines.
Guy
those are all good suggestions. good luck on your proposed guidelines.
Guy
September 3, 2009 |
[Guy Weinberg]
[Guy Weinberg]
But Intralipid is absent in my country.
So, since 2006 autumn here in Ukraine we have to buy Lipofundin (BBraun) for operating theatres.
But now, after French article by Mazoit et al in Anesthesiology 2009; 110 (2): 380-6, I'm not sure Lipofundin is as good as Intralipid.
Besides, our team now has an order from Ukrainian Ministry of Health to write guidelines for LA toxicity management.
It would be rather stupid to recommend in the guidelines Intralipid, absent in the Ukrainian market.
The most curious is the fact that we have firms representing Fresenius Kabi here, but we cannot obtain Intralipid.
Can anybody give me e-mail address of central office or the pan-European product-manager of the Intralipid manufacturer?